欢迎来到天天文库
浏览记录
ID:55060393
大小:179.73 KB
页数:3页
时间:2020-05-08
《恩替卡韦对不同病毒载量慢性乙型肝炎患者的长期疗效观察-论文.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、里堕堕堡兰堡垄志2014年4月第41卷第2期InterJEpidemiolInfectDis,April2014,Vo1.41,No.2·95··论著·恩替卡韦对不同病毒载量慢性乙型肝炎患者的长期疗效观察罗国庆张长【摘要】目的探讨长期应用恩替卡韦(ETV)对不同HBVDNA载量的慢性乙型肝炎患者的疗效。方法77例患者参照GLOBE研究方案,对基线HBVDNA>IO拷贝/mL的5O例与HBVDNA2、指标,并对治疗后的应答情况进行分析。结果ETV治疗157周时基线HBVDNA>10拷贝/mL和<10拷贝/mL者的完全病毒学应答率分别为80.0%和77.8%=0.053,P>0.05),两组HBeAg阴转率和HBeAg血清转换率分别为46.0%、42.0%和63.0%、63.O%,差异没有统计学意义=2.021和3.082,P均>0.05)。两组ALT复常率分别为90.0%和85.2%,差异无统计学意义=0.394,P>0.05)。结论长疗程恩替卡韦治疗不同基线HBVDNA水平慢性乙型肝炎的疗效基本相同。【关键词】肝炎,乙型,慢性;3、HBeAg;HBVDNA;恩替卡韦Eficacyoflong—-termentecavirtreatmentforchronichepatitisBpatientswithdiferenthepatitisBviralloadsLuoGuoqing*,ZhangChang.*DepartmentofLiverDiseases,WenlingTraditionalChineseMedicineHas—pitalAfiliatedtoZhejiangChineseMedicalUniversity,Wenling317500,Zhejia4、ng,ChinaCorrespondingauthor:ZhangChang,E—mail:wlzc0812@163.corn【Abstract】ObjectiveToexploretheeficacyoflong-tem3entecavirtreatmentforchronichepatitisBpatientswithdifferentHBVDNAloads.MethodsAccordingtoGLOBEresearchprogram,77patientsreceivedantiretroviraltherapybyentecav5、ir,including50patientswithHBVDNA>10copies/mLand27patientswithHBVDNA<10copies/mL.ALTlevels.HBVDNAloads.andtheserummarkersofhepatitisBweredetectedbeforeand24.48.96and157weeksaftertreatmentandcomparedbetweentwogroups.Theresponseratewasanalyzed.ResultsAfter157一weektreatment6、withentecavir,thecompletevirologicalresponserateofthepatientswithbaselineHBVDNA>107copies/mLand<10copies/mLwere80.0%and77.8%(=0.053,P>0.05),respectively;HBeAgnegativerateandHBeAgserologicalresponseratewere46.0%,42.0%and63.0%,63.0%,respectively(=2.021and3.082,Ps>0.05);th7、eALTrecoveryratewere90.0%and85.2%,respectively(=0.394,P>O.05).ConclusionsTheeffectoflong—termentecavironchronichepatitisBisirrespectiveofbaselinelevelsofHBVDNA.【Keywords】HepatitisB,chronic;HBeAg;HBVDNA;Entecavir美国肝脏病学会,欧洲肝病学会与亚太肝病学阳性慢性乙型肝炎(CHB)不同HBVDNA水平患者会一致将恩替卡韦(ETV)列8、为强效、低耐药的一线抗的长期疗效进行评估。病毒药物。本研究对77例ETV初始治疗HBeAg对象与方法DOI:10.3760/cma.j.issn.1673—4149.2014.02.006一、病例来源作者单位:31750
2、指标,并对治疗后的应答情况进行分析。结果ETV治疗157周时基线HBVDNA>10拷贝/mL和<10拷贝/mL者的完全病毒学应答率分别为80.0%和77.8%=0.053,P>0.05),两组HBeAg阴转率和HBeAg血清转换率分别为46.0%、42.0%和63.0%、63.O%,差异没有统计学意义=2.021和3.082,P均>0.05)。两组ALT复常率分别为90.0%和85.2%,差异无统计学意义=0.394,P>0.05)。结论长疗程恩替卡韦治疗不同基线HBVDNA水平慢性乙型肝炎的疗效基本相同。【关键词】肝炎,乙型,慢性;
3、HBeAg;HBVDNA;恩替卡韦Eficacyoflong—-termentecavirtreatmentforchronichepatitisBpatientswithdiferenthepatitisBviralloadsLuoGuoqing*,ZhangChang.*DepartmentofLiverDiseases,WenlingTraditionalChineseMedicineHas—pitalAfiliatedtoZhejiangChineseMedicalUniversity,Wenling317500,Zhejia
4、ng,ChinaCorrespondingauthor:ZhangChang,E—mail:wlzc0812@163.corn【Abstract】ObjectiveToexploretheeficacyoflong-tem3entecavirtreatmentforchronichepatitisBpatientswithdifferentHBVDNAloads.MethodsAccordingtoGLOBEresearchprogram,77patientsreceivedantiretroviraltherapybyentecav
5、ir,including50patientswithHBVDNA>10copies/mLand27patientswithHBVDNA<10copies/mL.ALTlevels.HBVDNAloads.andtheserummarkersofhepatitisBweredetectedbeforeand24.48.96and157weeksaftertreatmentandcomparedbetweentwogroups.Theresponseratewasanalyzed.ResultsAfter157一weektreatment
6、withentecavir,thecompletevirologicalresponserateofthepatientswithbaselineHBVDNA>107copies/mLand<10copies/mLwere80.0%and77.8%(=0.053,P>0.05),respectively;HBeAgnegativerateandHBeAgserologicalresponseratewere46.0%,42.0%and63.0%,63.0%,respectively(=2.021and3.082,Ps>0.05);th
7、eALTrecoveryratewere90.0%and85.2%,respectively(=0.394,P>O.05).ConclusionsTheeffectoflong—termentecavironchronichepatitisBisirrespectiveofbaselinelevelsofHBVDNA.【Keywords】HepatitisB,chronic;HBeAg;HBVDNA;Entecavir美国肝脏病学会,欧洲肝病学会与亚太肝病学阳性慢性乙型肝炎(CHB)不同HBVDNA水平患者会一致将恩替卡韦(ETV)列
8、为强效、低耐药的一线抗的长期疗效进行评估。病毒药物。本研究对77例ETV初始治疗HBeAg对象与方法DOI:10.3760/cma.j.issn.1673—4149.2014.02.006一、病例来源作者单位:31750
此文档下载收益归作者所有